1 Internal Medicine Department, General

Hospital Western Attiki -General Hospital

“Agios Panteleimon”, Nikaia, Pireaus, Greece;

2 1st Department of Internal Medicine,

General Hospital “Agios Panteleimon”-

General Hospital Western Attiki, Nikaia,

Pireaus, Greece;

3 Department of Gastroenterology, National

&Kapodistrian University of Athens, Laiko

General Hospital, Athens, Greece;

4 Biopathology Medicine Department, General

Hospital Western Attiki-General Hospital

“Agios Panteleimon”, Nikaia, Pireaus, Greece;

To emphasize the importance of a

prompt evaluation of recommended

DAA regimens and their vital

contribution to CHC treatment ,

especially to patients with several

comorbidities.

We included CHC pantients who have been treated with the

currently recommended by AASLD DAA regimens and had

completed the treatment the 30th of September.The stage of liver

disease was assessed mainly with transient elastography. Results:80

patients,( 68% of them were males),70% patients had failed to

previous regimen(s) including pegylated interferon

(Peg)+ribavirin.The main source of infection was blood transfusion

and i.v. drug use (60%). Genotype distribution was 11% G1a, 26%

G1b, 3% G2, 45% G3 and 15% G4. 57% were F4 by Metavir score

and 43% F3 .The regimens used were: 3D±R x12wks (n=25),

2D+R x12wks (n=12), SOF+daclatasvir±R x12wks (n=7),

Peg+R+sofosbuvir (SOF) x12wks (n=9), SOF+R x12 (n=10),

SOF+simeprevir±R x12wks (n=10), Harvoni±R x12wks (n=5).

One patient died during treatment due to lung-cancer diagnosis

and one had an episode of hepatic encephalopathy. There were no

additional early treatment discontinuations. Sustained virological

response (SVR) has been achieved in 96% .

The treatment of CHC with 2nd

generation DAAs was excellent

tolerated, had low rates of SAEs or

treatment discontinuation , but there is

always need for more advanced and

specified treatment for persisting CHC

and relapsed patients.